EMPAVELI (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced ...
Weight loss is complex. Traditional metrics like kilograms lost and BMI tell only part of the story. The next era of obesity trials demands evidence that goes underneath the lost kilos, evidence that ...
Rocco’s Honda & Acura Specialists operates as a full-service automotive facility in Palmdale. The company provides Honda and Acura service, routine maintenance, and vehicle repair. Its team of ...
BASF Agricultural Solutions will establish more than 50 new global corporate and governance roles in Bucharest in a move to ...
Iptacopan is a complement factor B inhibitor targeting the overactive alternative complement pathway in IgA nephropathy.
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta gr ...
Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy. The complement inhibitor was granted accelerated approved in 2024; continued ...
Persistent kidney inflammation is a hallmark of IgAN, and a key driver of disease progression, leading to ongoing kidney damage and loss of function over time,” said Vlado Perkovic, MD, Professor of ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — SEATTLE--(BUSINESS WIRE)--Omeros ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — Omeros Corporation (NASDAQ: OMER) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results